<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Fosphenytoin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i880.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i880.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i880.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i276.htm">Antiepileptics</a> &gt; <a href="41001i284.htm">Phenytoin</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i284.htm" title="Previous: Phenytoin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i857.htm" title="Next: Tiagabine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i880">Fosphenytoin</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Fosphenytoin</b>
          has no specific interaction information.
        </p><div>Fosphenytoin interactions as for phenytoin</div><p>Fosphenytoin belongs to <b>Phenytoin</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























































































































<tr><td><a href="41001i907.htm">Abacavir</a></td><td> phenytoin possibly reduces plasma concentration of abacavir </td><td></td></tr><tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>plasma concentration of  phenytoin possibly increased by acetazolamide </b></td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td>plasma concentration of  phenytoin possibly reduced by chronic heavy consumption of alcohol </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>metabolism of  phenytoin inhibited by amiodarone (increased plasma concentration)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  phenytoin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b> phenytoin possibly reduces plasma concentration of tricyclics </b></td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> phenytoin possibly reduces plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> phenytoin possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td>effects of  phenytoin enhanced by aspirin </td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td>plasma concentration of  phenytoin possibly increased or decreased by benzodiazepines </td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  phenytoin advised by manufacturer of boceprevir (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td> phenytoin reduces plasma concentration of bupropion </td><td></td></tr><tr><td><a href="41001i993.htm">Busulfan</a></td><td> phenytoin possibly reduces plasma concentration of busulfan </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  phenytoin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of both drugs often reduced when  phenytoin given with carbamazepine , also plasma concentration of phenytoin may be increased</td><td></td></tr><tr><td><a href="41001i550.htm">Carbonic Anhydrase Inhibitors</a></td><td>increased risk of osteomalacia when  phenytoin given with carbonic anhydrase inhibitors </td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td> phenytoin possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i158.htm">Chloramphenicol</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by chloramphenicol (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i374.htm">Chlorpromazine</a></td><td>plasma concentration of  phenytoin possibly increased or decreased by chlorpromazine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> phenytoin accelerates metabolism of ciclosporin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>metabolism of  phenytoin inhibited by cimetidine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>plasma concentration of  phenytoin increased or decreased by ciprofloxacin </td><td></td></tr><tr><td><a href="41001i877.htm">Cisplatin</a></td><td>plasma concentration of  phenytoin possibly reduced by cisplatin </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>metabolism of  phenytoin inhibited by clarithromycin (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i408.htm">Clonazepam</a></td><td> phenytoin often reduces plasma concentration of clonazepam </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> phenytoin accelerates metabolism of clozapine (reduced plasma concentration)</td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1108.htm">Colesevelam</a></td><td>absorption of  phenytoin possibly reduced by colesevelam </td><td>Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td class="cBV"><b> phenytoin accelerates metabolism of corticosteroids (reduced effect)</b></td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> phenytoin accelerates metabolism of coumarins (possibility of reduced anticoagulant effect, but enhancement also reported)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td> phenytoin possibly reduces plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td> phenytoin possibly reduces plasma concentration of darunavir </td><td></td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td>plasma concentration of  phenytoin increased or decreased by diazepam </td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>plasma concentration of  phenytoin reduced by diazoxide , also effect of diazoxide may be reduced</td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> phenytoin possibly reduces plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by diltiazem but also effect of diltiazem reduced</b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td> phenytoin reduces plasma concentration of disopyramide </td><td></td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td class="cBV"><b>metabolism of  phenytoin inhibited by disulfiram (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i212.htm">Doxycycline</a></td><td> phenytoin accelerates metabolism of doxycycline (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> phenytoin possibly reduces plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i830.htm">Enteral Foods</a></td><td>absorption of  phenytoin possibly reduced by enteral feeds </td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1205.htm">Eribulin</a></td><td> phenytoin possibly reduces plasma concentration of eribulin </td><td></td></tr><tr><td><a href="41001i1153.htm">Eslicarbazepine</a></td><td> phenytoin reduces plasma concentration of eslicarbazepine , also plasma concentration of phenytoin increased</td><td></td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>effects of  phenytoin enhanced by esomeprazole </b></td><td></td></tr><tr><td><a href="41001i281.htm">Ethosuximide</a></td><td class="cBV"><b>plasma concentration of  phenytoin possibly increased by ethosuximide , also plasma concentration of ethosuximide possibly reduced</b></td><td></td></tr><tr><td><a href="41001i1031.htm">Etoposide</a></td><td> phenytoin possibly reduces plasma concentration of etoposide </td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>avoidance of  phenytoin advised by manufacturer of etravirine </td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td> phenytoin reduces effects of felodipine </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by fluconazole (consider reducing dose of phenytoin)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i509.htm">Fluorouracil</a></td><td>metabolism of  phenytoin possibly inhibited by fluorouracil (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by fluoxetine </b></td><td></td></tr><tr><td><a href="41001i603.htm">Fluvastatin</a></td><td>combination of  phenytoin with fluvastatin may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by fluvoxamine </b></td><td></td></tr><tr><td><a href="41001i860.htm">Folates</a></td><td>plasma concentration of  phenytoin possibly reduced by folates </td><td></td></tr><tr><td><a href="41001i542.htm">Furosemide</a></td><td> phenytoin antagonises effects of furosemide </td><td></td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td>avoidance of  phenytoin advised by manufacturer of gefitinib </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> phenytoin reduces plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of imatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> phenytoin possibly reduces plasma concentration of indinavir , also plasma concentration of phenytoin possibly increased</b></td><td></td></tr><tr><td><a href="41001i758.htm">Influenza Vaccine</a></td><td>effects of  phenytoin enhanced by influenza vaccine </td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td> phenytoin reduces plasma concentration of irinotecan and its active metabolite</td><td></td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td>metabolism of  phenytoin possibly inhibited by isoniazid (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i472.htm">Isradipine</a></td><td>avoidance of  phenytoin advised by manufacturer of isradipine </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of itraconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of ketoconazole </b></td><td></td></tr><tr><td><a href="41001i283.htm">Lamotrigine</a></td><td> phenytoin reduces plasma concentration of lamotrigine </td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  phenytoin advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i891.htm">Leflunomide</a></td><td>plasma concentration of  phenytoin possibly increased by leflunomide </td><td>Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</td></tr><tr><td><a href="41001i1032.htm">Levamisole</a></td><td>plasma concentration of  phenytoin possibly increased by levamisole </td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td> phenytoin possibly reduces effects of levodopa </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>neurotoxicity may occur when  phenytoin given with lithium without increased plasma concentration of lithium</td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td> phenytoin possibly reduces plasma concentration of lopinavir </td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> phenytoin accelerates metabolism of methadone (reduced effect and risk of withdrawal effects)</td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> phenytoin increases antifolate effect of methotrexate </td><td></td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>plasma concentration of  phenytoin increased by methylphenidate </td><td></td></tr><tr><td><a href="41001i170.htm">Metronidazole</a></td><td>metabolism of  phenytoin possibly inhibited by metronidazole (increased plasma concentration)</td><td>Interactions do not apply to topical metronidazole preparations </td></tr><tr><td><a href="41001i254.htm">Mianserin</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of mianserin </b></td><td></td></tr><tr><td><a href="41001i299.htm">Miconazole</a></td><td class="cBV"><b>anticonvulsant effect of  phenytoin enhanced by miconazole (plasma concentration of phenytoin increased)</b></td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td> phenytoin reduces plasma concentration of mirtazapine </td><td></td></tr><tr><td><a href="41001i847.htm">Modafinil</a></td><td>plasma concentration of  phenytoin possibly increased by modafinil </td><td></td></tr><tr><td><a href="41001i620.htm">Muscle Relaxants, non-depolarising</a></td><td> phenytoin antagonises muscle relaxant effect of non-depolarising muscle relaxants (accelerated recovery from neuromuscular blockade)</td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  phenytoin reduced by nelfinavir </td><td></td></tr><tr><td><a href="41001i476.htm">Nimodipine</a></td><td>avoidance of  phenytoin advised by manufacturer of nimodipine (plasma concentration of nimodipine possibly reduced)</td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> phenytoin accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>effects of  phenytoin possibly enhanced by omeprazole </td><td></td></tr><tr><td><a href="41001i1045.htm">Ondansetron</a></td><td> phenytoin accelerates metabolism of ondansetron (reduced effect)</td><td></td></tr><tr><td><a href="41001i900.htm">Oxcarbazepine</a></td><td>plasma concentration of  phenytoin increased by oxcarbazepine , also plasma concentration of an active metabolite of oxcarbazepine reduced</td><td></td></tr><tr><td><a href="41001i59.htm">Paracetamol</a></td><td> phenytoin possibly accelerates metabolism of paracetamol (also isolated reports of hepatotoxicity)</td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td> phenytoin reduces plasma concentration of paroxetine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td> phenytoin often increases plasma concentration of phenobarbital , plasma concentration of phenytoin often reduced but may be increased</td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td class="cBV"><b> phenytoin accelerates metabolism of progestogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>anticonvulsant effect of  phenytoin antagonised by pyrimethamine , also increased antifolate effect</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td> phenytoin accelerates metabolism of quetiapine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1195.htm">Retigabine</a></td><td> phenytoin possibly reduces plasma concentration of retigabine </td><td></td></tr><tr><td><a href="41001i199.htm">Rifamycins</a></td><td class="cBV"><b>metabolism of  phenytoin accelerated by rifamycins (reduced plasma concentration)</b></td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td> phenytoin possibly reduces plasma concentration of ritonavir , also plasma concentration of phenytoin possibly affected</td><td></td></tr><tr><td><a href="41001i1102.htm">Rufinamide</a></td><td> phenytoin possibly reduces plasma concentration of rufinamide , also plasma concentration of phenytoin possibly increased</td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> phenytoin possibly reduces plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td>plasma concentration of  phenytoin possibly increased by sertraline , also plasma concentration of sertraline possibly reduced</td><td></td></tr><tr><td><a href="41001i1144.htm">Stiripentol</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by stiripentol </b></td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td class="cBV"><b>absorption of  phenytoin reduced by sucralfate </b></td><td></td></tr><tr><td><a href="41001i689.htm">Sulfinpyrazone</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by sulfinpyrazone </b></td><td></td></tr><tr><td><a href="41001i203.htm">Sulfonamides</a></td><td>plasma concentration of  phenytoin possibly increased by sulfonamides </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td> phenytoin reduces plasma concentration of tacrolimus , also plasma concentration of phenytoin possibly increased</td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  phenytoin advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b> phenytoin reduces plasma concentration of telithromycin (avoid during and for 2 weeks after phenytoin)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b>plasma concentration of both drugs reduced when  phenytoin given with theophylline </b></td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td> phenytoin accelerates metabolism of thyroid hormones (may increase requirements in hypothyroidism), also plasma concentration of phenytoin possibly increased</td><td></td></tr><tr><td><a href="41001i857.htm">Tiagabine</a></td><td> phenytoin reduces plasma concentration of tiagabine </td><td></td></tr><tr><td><a href="41001i737.htm">Tibolone</a></td><td> phenytoin accelerates metabolism of tibolone </td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td> phenytoin possibly reduces plasma concentration of ticagrelor </td><td></td></tr><tr><td><a href="41001i275.htm">Tolbutamide</a></td><td>plasma concentration of  phenytoin transiently increased by tolbutamide (possibility of toxicity)</td><td></td></tr><tr><td><a href="41001i285.htm">Topiramate</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by topiramate (also plasma concentration of topiramate reduced)</b></td><td></td></tr><tr><td><a href="41001i582.htm">Toremifene</a></td><td> phenytoin possibly accelerates metabolism of toremifene </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by trimethoprim (also increased antifolate effect)</b></td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  phenytoin advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  phenytoin increased or possibly reduced when given with valproate , also plasma concentration of valproate reduced</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td> phenytoin reduces effects of verapamil </td><td></td></tr><tr><td><a href="41001i287.htm">Vigabatrin</a></td><td>plasma concentration of  phenytoin reduced by vigabatrin </td><td></td></tr><tr><td><a href="41001i768.htm">Vitamin D</a></td><td> phenytoin possibly increases requirements for vitamin D </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  phenytoin increased by voriconazole , also phenytoin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for phenytoin toxicity)</b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td>plasma concentration of  phenytoin increased or decreased by zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr><tr><td><a href="41001i1040.htm">Zonisamide</a></td><td> phenytoin reduces plasma concentration of zonisamide </td><td></td></tr></tbody></table><p>Fosphenytoin belongs to <b>Antiepileptics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by SSRIs (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by tricyclics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i252.htm">Antidepressants, Tricyclic (related)</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics possibly antagonised by tricyclic-related antidepressants (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by antipsychotics (convulsive threshold lowered)</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td>possible increased risk of convulsions when  antiepileptics given with chloroquine and hydroxychloroquine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td>anticonvulsant effect of  antiepileptics possibly antagonised by MAOIs (convulsive threshold lowered)</td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by mefloquine </b></td><td></td></tr><tr><td><a href="41001i856.htm">Orlistat</a></td><td class="cBV"><b>possible increased risk of convulsions when  antiepileptics given with orlistat </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>avoid concomitant use of  antiepileptics with St John's wort </b></td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i284.htm">Previous: Phenytoin</a> | <a class="top" href="41001i880.htm#">Top</a> | <a accesskey="]" href="41001i857.htm">Next: Tiagabine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>